Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study.

Sikjaer T, Rejnmark L, Thomsen JS, Tietze A, Brüel A, Andersen G, Mosekilde L

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Apr 2012Cited by 60 (Europe PMC)

PMID22161686DOI10.1002/jbmr.1493PepBankPUB-22161686

Source link PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, PTH produced 27% lower trabecular thickness versus placebo (p < 0.01).
In plain wordsIn hypoparathyroidism, PTH produced 27% thinner bone trabeculae than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseTrabecular thickness
Study
n = 44
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Trabecular thickness difference
27%
PTH vs placebo, lower
Source sentences
Summary
Compared with placebo, PTH caused a 27% lower trabecular thickness (p < 0.01) and 4% lower trabecular bone tissue density (p < 0.01), whereas connectivity density was 34% higher (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168601
02HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, PTH produced 4% lower trabecular bone tissue density versus placebo (p < 0.01).
In plain wordsIn hypoparathyroidism, PTH produced 4% lower trabecular bone tissue density than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseTrabecular bone tissue density
Study
n = 44
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Trabecular bone tissue density difference
4%
PTH vs placebo, lower
Source sentences
Summary
Compared with placebo, PTH caused a 27% lower trabecular thickness (p < 0.01) and 4% lower trabecular bone tissue density (p < 0.01), whereas connectivity density was 34% higher (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168602
03HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, PTH produced 34% higher connectivity density versus placebo (p < 0.05).
In plain wordsIn hypoparathyroidism, PTH produced 34% higher bone connectivity density than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseConnectivity density
Study
n = 44
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Connectivity density difference
34%
PTH vs placebo, higher
Source sentences
Summary
Compared with placebo, PTH caused a 27% lower trabecular thickness (p < 0.01) and 4% lower trabecular bone tissue density (p < 0.01), whereas connectivity density was 34% higher (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168603
04HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, PTH produced 139% more Haversian canals per area versus placebo (p = 0.01).
In plain wordsIn hypoparathyroidism, PTH produced 139% more Haversian canals per area than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseHaversian canals per area
Study
n = 44
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Haversian canals per area difference
139%
PTH vs placebo, higher
Source sentences
Summary
At cortical bone, number of Haversian canals per area was 139% higher (p = 0.01) in the PTH group, causing a tendency toward an increased cortical porosity (p = 0.09).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168607
05HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, PTH showed a tendency toward increased cortical porosity versus placebo (p = 0.09).
In plain wordsIn hypoparathyroidism, PTH showed a tendency toward greater cortical porosity than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseCortical porosity
Study
n = 44
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
At cortical bone, number of Haversian canals per area was 139% higher (p = 0.01) in the PTH group, causing a tendency toward an increased cortical porosity (p = 0.09).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168608
06HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, PTH decreased lumbar spine areal BMD by 1.8% versus placebo (p < 0.05).
In plain wordsIn hypoparathyroidism, PTH decreased spine areal bone density by 1.8% versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseLumbar spine areal BMD
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Lumbar spine aBMD change
1.8%
PTH vs placebo, decrease
Source sentences
Summary
However, at the lumbar spine, aBMD decreased by 1.8% (p < 0.05), whereas vBMD increased by 12.8% (p = 0.02) in the PTH compared with the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168611
07HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, PTH increased lumbar spine volumetric BMD by 12.8% versus placebo (p = 0.02).
In plain wordsIn hypoparathyroidism, PTH increased spine volumetric bone density by 12.8% versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine volumetric BMD
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Lumbar spine vBMD change
12.8%
PTH vs placebo, increase
Source sentences
Summary
However, at the lumbar spine, aBMD decreased by 1.8% (p < 0.05), whereas vBMD increased by 12.8% (p = 0.02) in the PTH compared with the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168612
08HumanNon-randomized trialEfficacy outcome
In hypoparathyroidism, trabecular tunneling appeared in 11 biopsies (48%) from PTH-treated patients.
In plain wordsIn hypoparathyroidism, bone tunneling appeared in 48% of biopsies from PTH-treated patients.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Not applicableTrabecular tunneling
Study
n = 23
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Biopsies with trabecular tunneling
11 biopsies
PTH group
Biopsies with trabecular tunneling
48%
PTH group
Source sentences
Summary
Trabecular tunneling was evident in 11 (48%) of the biopsies from the PTH group.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168604
09HumanNon-randomized trialEfficacy outcome
In hypoparathyroidism, hip subregion areal BMD decreased during PTH treatment within the reported 1% to 4% range.
In plain wordsIn hypoparathyroidism, hip areal bone density decreased during PTH treatment within the reported 1% to 4% range.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseHip areal BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Hip BMD decrease (range across subregions)
1 to 4%
PTH group, hip subregions
Source sentences
Summary
At different subregions of the hip, areal BMD (aBMD) and volumetric BMD (vBMD), as assessed by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), decreased significantly by 1% to 4% in the PTH group.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168609
10HumanNon-randomized trialEfficacy outcome
In hypoparathyroidism, hip subregion volumetric BMD decreased during PTH treatment within the reported 1% to 4% range.
In plain wordsIn hypoparathyroidism, hip volumetric bone density decreased during PTH treatment within the reported 1% to 4% range.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseHip volumetric BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Hip BMD decrease (range across subregions)
1 to 4%
PTH group, hip subregions
Source sentences
Summary
At different subregions of the hip, areal BMD (aBMD) and volumetric BMD (vBMD), as assessed by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), decreased significantly by 1% to 4% in the PTH group.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168610
11HumanObservational studyEfficacy outcome
In the hypoparathyroidism PTH study, tunneling was linked to significantly higher bone resorption markers.
In plain wordsIn the hypoparathyroidism PTH study, tunneling was linked to higher bone resorption markers.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseTunneling association with resorption markers
Study
n: not reported in source
Comparator
Patients without tunneling
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Patients with tunneling had significantly higher levels of biochemical markers of bone resorption and formation.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168605
12HumanObservational studyEfficacy outcome
In the hypoparathyroidism PTH study, tunneling was linked to significantly higher bone formation markers.
In plain wordsIn the hypoparathyroidism PTH study, tunneling was linked to higher bone formation markers.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseTunneling association with formation markers
Study
n: not reported in source
Comparator
Patients without tunneling
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Patients with tunneling had significantly higher levels of biochemical markers of bone resorption and formation.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess effects of PTH substitution therapy on 3-dimensional bone structure, we randomized 62 patients with hypoPT into 24 weeks of treatment with either PTH(1-84) 100 µg/day subcutaneously or similar placebo as an add-on therapy. Micro-computed tomography was performed on 44 iliac crest bone biop…
Report a problemFND-2216168606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.